Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cancer immunotherapy in patients with brain metastases

Research output: Contribution to journalReviewResearchpeer-review

  1. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Research output: Contribution to journalReviewResearchpeer-review

  4. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

    Research output: Contribution to journalReviewResearchpeer-review

  5. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

Original languageEnglish
JournalCancer immunology, immunotherapy : CII
Volume67
Issue number5
Pages (from-to)703-711
Number of pages9
ISSN0340-7004
DOIs
Publication statusPublished - May 2018

ID: 54806559